Skip to main content

Table 1 Clinical features of ADPKD and non-ADPKD patients on RRT

From: Renal replacement therapy in ADPKD patients: a 25-year survey based on the Catalan registry

 

ADPKD (n: 1586)

Non ADPKD (n: 18,447)

p

Age (years) at initiation of RRT in men

57.2 ± 12.7

60.9 ± 16.6

<0.001

Age (years) at initiation of RRT in women

57.8 ± 12.0

62.5 ± 17.0

<0.001

First choice of RRT (%)

HD 91.1%

HD 89.4%

<0.01

TX 2.5%

TX 8.5%

PD 6.4%

PD 2.0%

RRT strategy at 31.12.2009 (%)1

HD 31.8%

HD 46.9%

<0.001

TX 65.4%

TX 49.3%

PD 2.8%

PD 3.8%

Time from initiation of RRT to TX (years)2

2.9 (2.7-3.1)

3.1 (3.0-3.1)

p = 0.09

Age at TX (years)2

53.5 (52.9-54.0)

44.6 (44.2-44.9)

<0.001

Treated with ESA (%)1

77.9%

91.9%

<0.001

HCV (%)1

5.1%

10.0%

<0.001

CRP (<10 mg/l)1

71.7%

66.9%

0.124

  1. ADPKD Autosomal dominant polycystic kidney disease, RRT renal replacement therapy, HD haemodialysis, TX transplantation, PD peritoneal dialysis, ESA erythropoiesis stimulating agents, HCV hepatitis C virus, CRP C-reactive protein.
  2. 1Patients actively on RRT at 31 December 2009, 295% confidence intervals.